This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breton, M.
Right arrow Articles by Papadopoulou, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breton, M.
Right arrow Articles by Papadopoulou, B.

 Previous Article  |  Next Article 

Infection and Immunity, October 2005, p. 6372-6382, Vol. 73, No. 10
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.10.6372-6382.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis

Marie Breton, Michel J Tremblay, Marc Ouellette, and Barbara Papadopoulou*

Infectious Diseases Research Center, CHUL Research Center of Laval University, and Department of Medical Biology, Faculty of Medicine, Laval University, Quebec G1V 4G2, Canada

Received 4 April 2005/ Returned for modification 7 May 2005/ Accepted 21 June 2005

To date, there are no proven vaccines against any form of leishmaniasis. The development of live attenuated vectors shows promise in the field of Leishmania vaccination because these organisms mimic more effectively the course of real infections and can elicit potent activation of the immune system. In the present study, we investigated the potential of a parasitic protozoan that is nonpathogenic to humans, Leishmania tarentolae, as a live candidate vaccine that efficiently targets dendritic cells and lymphoid organs, thus enhancing antigen presentation and consequently influencing the magnitude and quality of T-cell immune responses. We demonstrated that L. tarentolae activates the dendritic cell maturation process and induces T-cell proliferation and the production of gamma interferon, thus skewing CD4+ T cells toward a Th1 cell phenotype. More importantly, we found that a single intraperitoneal injection of L. tarentolae could elicit a protective immune response against infectious challenge with Leishmania donovani in susceptible BALB/c mice. These results suggest that the use of L. tarentolae as a live vaccine vector may represent a promising approach for improving the effectiveness and safety of candidate live vaccines against Leishmania infections and possibly other intracellular pathogens for which T-cell mediated responses are critical for the development of protective immunity.

* Corresponding author. Mailing address: Infectious Diseases Research Center, CHUL Research Center, CHUQ, 2705 Laurier Blvd., Quebec (QC), Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: barbara.papadopoulou{at}crchul.ulaval.ca.

Editor: W. A. Petri, Jr.

Infection and Immunity, October 2005, p. 6372-6382, Vol. 73, No. 10
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.10.6372-6382.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dunning, N. (2009). Leishmania vaccines: from leishmanization to the era of DNA technology. Bioscience Horizons 2: 73-82 [Abstract] [Full Text]  
  • Breton, M., Zhao, C., Ouellette, M., Tremblay, M. J., Papadopoulou, B. (2007). A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J. Gen. Virol. 88: 217-225 [Abstract] [Full Text]  
  • Boitz, J. M., Ullman, B. (2006). A Conditional Mutant Deficient in Hypoxanthine-guanine Phosphoribosyltransferase and Xanthine Phosphoribosyltransferase Validates the Purine Salvage Pathway of Leishmania donovani. J. Biol. Chem. 281: 16084-16089 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»